Results 21 to 30 of about 2,872,365 (306)

Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation

JAMA - Journal of the American Medical Association, 2022
Importance During the COVID-19 pandemic, modified guidance for opioid agonist therapy (OAT) allowed prescribers to increase the number of take-home doses to promote treatment retention.
Tara Gomes, Daniel Werb
exaly   +2 more sources

Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Drugs in Context, 2023
The authors wish to make the following corrections to their article: Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on ...
Guido Mannaioni, Fabio Lugoboni
doaj   +2 more sources

Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon

Harm Reduction Journal, 2017
Background Opioid agonist therapy has been widely used to reduce harms among individuals with opioid use disorder but its effectiveness has not been evaluated in the Middle East North African (MENA) region.
Ali Ghaddar, Zeinab Abbas, Ramzi Haddad
doaj   +2 more sources

Federal opioid agonist therapy policy: interrupted time series analysis of the impact of the methadone exemption removal across eight provinces in Canada [PDF]

BMC Health Services Research
Background Federal deregulation of opioid agonist therapies are an attractive policy option to improve access to opioid use disorder care and achieve widespread beneficial impacts on growing opioid-related harms.
Abhimanyu Sud, Chloe Campbell, Arani Sivakumar, Ross Upshur, Rahim Moineddin, Kellia Chiu   +5 more
doaj   +2 more sources

Multimethod feasibility evaluation of smoking cessation intervention for patients receiving opioid agonist therapy [PDF]

Pilot and Feasibility Studies
Background Among patients receiving opioid agonist therapy, 85% are active tobacco smokers. Despite the significant impact of smoking-related pulmonary diseases on disability and mortality in this population, less than 10% successfully quit smoking with ...
Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Siv-Elin Leirvåg Carlsen, Einar Furulund, Jørn Henrik Vold, Jan Tore Daltveit, Torgeir Gilje Lid, Lars T. Fadnes, ATLAS4LAR Study Group   +8 more
doaj   +2 more sources

Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy

Addiction Science & Clinical Practice, 2022
Background The COVID-19 pandemic and consequent public health response may have undermined key responses to the protracted drug poisoning crisis, including reduced access to opioid agonist therapy (OAT) among people with opioid use disorder.
Soroush Moallef, Kora DeBeck, Nadia Fairbairn, Zishan Cui, Rupinder Brar, Dean Wilson, Cheyenne Johnson, M.-J. Milloy, Kanna Hayashi   +8 more
doaj   +3 more sources

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management

Molecules, 2020
Opioid analgesics are effective pain therapeutics but they cause various adverse effects and addiction. For safer pain therapy, biased opioid agonists selectively target distinct μ opioid receptor (MOR) conformations, while the potential of biased opioid
Wolfgang Sadee, John Oberdick, Zaijie Wang   +2 more
doaj   +2 more sources

Predictors of Enrollment in Opioid Agonist Therapy after Opioid Overdose or Diagnosis with Opioid Use Disorder: A cohort study

Drug and Alcohol Dependence, 2020
Background. Medicaid recipients have a high burden of opioid overdose and opioid use disorder (OUD). Opioid agonist therapies are an effective treatment for OUD, but there is a wide and persisting gap between those who are indicated and those who receive
Alexandria Macmadu, Kimberly Paull, R. Youssef, Sivakumar Batthala, Kevin H. Wilson, E. Samuels, Jesse L. Yedinak, B. Marshall   +7 more
semanticscholar   +3 more sources

Advances in the delivery of buprenorphine for opioid dependence

Drug Design, Development and Therapy, 2017
Richard N Rosenthal,1 Viral V Goradia2 1Department of Psychiatry, Addiction Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, 2Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA Abstract: Opioid use ...
Rosenthal RN, Goradia VV
doaj   +1 more source

Contraception Practices Among Women on Opioid Agonist Therapy [PDF]

Journal of Obstetrics and Gynaecology Canada, 2021
Despite increased public awareness and use of opioid agonist therapy (OAT), there is little published data on contraception among women on methadone or buprenorphine/naloxone. This study aimed to characterize patterns of contraception use among this population.We conducted a cross-sectional survey between May 2014 and October 2015 at 6 medical clinics,
Lingsa Jia, Wendy V. Norman
openaire   +3 more sources